AzTrials
AzTrials

ObeseEarly Phase 1NCT02596776

Cold Induced Changes in White Adipose

A Early Phase 1 study testing Fat biopsy, Propranolol and fat biopsy and heavy water and fat biopsy in people with Obese and Normal Body Weight, run by Philip Kern at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

An adaptation to a cold environment is a tendency to generate heat within our body. Some of this heat comes from our fat tissue. Although most fat tissue is "white fat", there are pockets deep within the body that are called "brown fat", which are specially adapted to burning fat and making heat. Read more about this study

Who is it for?
Ages 35 to 60 years, women onlyHealthy volunteers can take part
Conditions the study is for
Obese, Normal Body Weight, Prediabetes
What is being tested?
Fat biopsy, Propranolol and fat biopsy and heavy water and fat biopsy
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
26 participants
Where
1 siteUnited States
Study dates
Mar 2016to 20 Aug 2018
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 35 to 60 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • the lean subjects body mass index (BMI) < 27
  • subjects with obesity/MetS (BMI 27-45 with IGT, IFG, or 3 features of MetS)
  • Insulin resistance Fasting blood sugar >126, or 2 hr glu >200, but with A1C<7.5 (i.e. we will include subjects with T2DM on no meds and with good glycemic control)
  • adequate platelet count (>100,000)
  • hematocrit of >32
  • stable weight

Who cannot join

  • obese subjects (BMI > 45)
  • anti-inflammatory drugs, β-blockers, any diabetes drugs or drugs known to affect adipose tissue
  • an unstable medical condition
  • coronary artery disease
  • congestive heart failure
  • heart block or a history of or any contraindication to a β-blocker.
Show all 11Show fewer
  • asthma
  • previous stroke
  • use of anticoagulants or aspirin
  • pregnant or breastfeeding
  • lifestyles involving absent or extreme temperature exposure (eg. homebound or institutionalized subjects, outdoor workers).

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Kentucky Medical Center Center for Clinical and Translational Science

    Lexington, Kentucky, 40536

Other trials in United States

About this study

Official title: Cold Induced Changes in Human Subcutaneous White Adipose

An adaptation to a cold environment is a tendency to generate heat within our body. Some of this heat comes from our fat tissue. Although most fat tissue is "white fat", there are pockets deep within the body that are called "brown fat", which are specially adapted to burning fat and making heat. The investigator believes that our white fat, just underneath the surface of our skin, also has this property to burn fat and make heat, although not at the high level of brown fat. This study is to examine this fat-burning property of the white fat under the skin in response to seasons and to cold. Many such studies have been done in mice, but little has been done in humans.

There are a number of factors, including age, weight, and medical history, that may make a person eligible or ineligible to participate in this study. Certain medications could make a person ineligible, but if these medications can be safely altered, the individual may become eligible.

Read the detailed description

Metabolic syndrome is a condition involving elevated levels of fat in the blood, a tendency towards diabetes, hypertension, and too much fat around the abdomen (an increased waistline). Individuals with metabolic syndrome often have impaired glucose tolerance, which is a condition where blood sugar is normal before a person eats, but is too high after drinking a sugary drink. This is due to an abnormality in the body's sensitivity to insulin (insulin resistance), which is due in part to an inability of muscle to take up glucose. People with metabolic syndrome have inflammation in their fat tissue and this inflammation in the fat tissue may impair the ability of the white fat to burn fat and continue to promote obesity.

This study involves three arms. A propranolol with biopsy arm, a heavy water with biopsy arm, and a biopsy only arm. The goal is to understand the response of fat to cold, either acutely, or after repeated cold exposure, or in response to a change in seasons.

Individuals (subjects) accepted into the study will report to the UK Center for Clinical and Translational Science (CCTS) research unit for baseline testing and repeated procedures. Participants will then be asked to have the same procedures done approximately 6 months later.

Subjects enrolled into the study will need to come to the CCTS Unit for multiple visits. Most of these visits will be less than 1 hour, but 6 visits will involve procedures and will vary in time ranging from 4 hour to 6 hours. If a subject participates in all aspects of the study (fat biopsy from multiple depots, short term, long term, and seasons, then their total participation will be approximately 28 visits over 6-7 months. However, for most subjects, their participation will involve fewer visits, at the discretion of the principal investigator.

The first visit will involve the consent process, followed by baseline fasting blood samples and the oral glucose tolerance test. If the subject passes these screening procedures, then subsequent visits will involve the fat biopsies, DEXA, and other visits described below.

Fat biopsies (Visits 2, 14, 17 and 28). Regardless of the study arm assigned to all subjects will present to the CCTS fasting and a baseline fat biopsy will be performed on the thigh and lower abdomen. Abdominal and thigh subcutaneous adipose tissue will be removed by incision under local anesthesia. An ice pack will then be placed on the opposite thigh and lower abdomen for 30 min; 4 hr later, an adipose biopsy will be obtained from the iced area. The subject will then report to the CCTS daily for repeated 30 min ice pack procedures. However, at the discretion of the PI, participant may be able to perform the 30 min ice pack procedure at home. On day 7 and on day 14, subjects will report to the CCTS fasting and the above procedure will be repeated: an ice pack will be placed on the thigh and abdomen for 30 min, and fat biopsies will be taken from the iced area and from the non-iced area 4 hr later.

Propranolol Arm: Subjects who qualify for this subgroup will be given propranolol 10 mg three times per day. If they tolerate the medication well with no side effects, after 5 days, they will then increase the dose to 20 mg three times per day. If they tolerate the 20 mg dose well with no side effects, after another 5 days (day 10), they will then increase the dose to 40 mg three times per day and stay on this for the duration of the study.

Heavy Water Arm: Subjects who qualify for this subgroup will be given heavy water (at visit 2) every 3 hours for the next 12 hours while at the CCTS. They will then be sent home with doses of heavy water in sealed sterile vials, and will take one vial of heavy water twice per day for 5 weeks.

The following test and procedures will be performed on subjects:

Glucose tolerance test (Visits 1 and 15). This will be a standard oral glucose tolerance test using 75 g of glucose, with blood for glucose and insulin drawn at times 1, 30, 60, 90, and 120 min.

Resting metabolic rate. The investigator will measure resting metabolic rate (RMR). RMR is measured early in the morning, fasting, in a room on the CCTS.

DEXA. Body composition will be measured with DEXA.

12-Lead ECG: To examine heart rhythm and heart rate and any evidence of previous heart disease.

Urine Collection: Females who are capable of becoming pregnant will also be given a urine pregnancy test. If the test results show that they are pregnant they will not be able to participate in the study.

Unscheduled Visits: During the study if either the subject or the PI feel that that the subject should be seen for an additional visit due to an adverse event, the study staff will arrange for this visit. This visit should take no more than 30 minutes. During this visit the investigator will:

  • Review subject's current medication use, including over the counter medications and herbals.
  • Ask the subject questions about their health or any problems they may have had since their last visit.
  • If necessary, take a blood sample (about 1 tablespoon) and urine sample (about 6 teaspoons) to monitor the subject's general health.
  • If necessary, perform a ECG and measure blood pressure and pulse.
  • If necessary, ask questions about how study drug dosing at home.

After completing the above procedure, the subject will be asked to come back for the same set of procedures the following season (i.e. winter, if original procedure was summer, or vice versa).

Therefore, if the subject completes all the procedures in both seasons, a total of 16 biopsies will be performed. Following initial studies, the investigator may refine the protocol and take fewer biopsies. For example, if early experiments determine that abdominal fat is not responsive to seasons, the investigator may discontinue this procedure. The investigator may determine that the baseline fat biopsy (prior to icing) is unnecessary.

Being tested
Fat biopsy, Propranolol and fat biopsy, heavy water and fat biopsy
Medical subject headings
Obesity, Prediabetic State, Metabolic Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fat biopsyProcedure or surgery

    up to 16 biopsy samples will be taken from each subject

  • Propranolol and fat biopsyDrug

    subset of subjects will receive propranolol and have fat biopsy performed

  • heavy water and fat biopsyOther

    subset of subjects will be given heavy water and have fat biopsy performed

Study groups in NCT02596776
Study groupRoleWhat they receive
Fat biopsyActive comparatorFrom each abdominal and thigh biopsy, between 0.5 - 3 g of tissue is obtained (often less from the thigh), which is used for immunohistochemistry and frozen for subsequent RNA or protein isolation.
Receives: Procedure: Fat biopsy
Propranolol and Fat BiopsyExperimentalFrom each abdominal and thigh biopsy, tissue will be examined for gene expression, with a focus on genes believed to be involved in adipose beiging (PGC1α, UCP1, TMEM26, IL4, Metrnl, CPA3, Siglec 8, tyrosine hydroxylase, others), and with immunohistochemistry, with a focus on beige adipocytes, macrophages, eosinophils and mast cells.
Receives: Procedure: Fat biopsy; Drug: Propranolol and fat biopsy
Heavy Water and Fat BiopsyActive comparatorThe investigator will measure in vivo adipose lipolysis and triglyceride (TG) turnover in response to cold to physiologically demonstrate the impact of cold exposure on tissue function. The subjects will then be given 50 mL sterile containers of 70% 2H2O and consume two 50 mL vials per day during the remainder of the 5-week labeling period. Plasma and urine will be collected weekly so that body 2H2O can be measured.
Receives: Procedure: Fat biopsy; Other: heavy water and fat biopsy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. WAT changes during repeated exposure to cold temperatures

    Adipose biopsies will be performed

    Measured: 28 Weeks (Summer and Winter Seasons)

  2. WAT changes following Propranolol dosing

    Subjects will be prescribed propranolol and adipose biopsies will be obtained.

    Measured: 17 days in the summer season

  3. In vivo measurement of adipose lipolysis and triglyceride (TG) turnover

    The heavy water will be given to and adipose biopsies will be obtained.

    Measured: 5 weeks per season (summer and winter)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Nov 2015 (estimated)
  2. Study startMar 2016
  3. Primary completion20 Aug 2018
  4. Study completion20 Aug 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
26 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02596776
Sponsor's protocol ID
15-0663
Other IDs
R01DK107646
Status last verified
Feb 2020
First submitted
2 Nov 2015
Last updated
7 Feb 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Publications

  • Finlin BS, Memetimin H, Confides AL, Kasza I, Zhu B, Vekaria HJ, Harfmann B, Jones KA, Johnson ZR, Westgate PM, Alexander CM, Sullivan PG, Dupont-Versteegden EE, Kern PA. Human adipose beiging in response to cold and mirabegron. JCI Insight. 2018 Aug 9;3(15):e121510. doi: 10.1172/jci.insight.121510. eCollection 2018 Aug 9.

    PubMed 30089732
  • Thiagarajan D, Quadri N, Jawahar S, Zirpoli H, Del Pozo CH, Lopez-Diez R, Hasan SN, Yepuri G, Gugger PF, Finlin BS, Kern PA, Gabbay K, Schmidt AM, Ramasamy R. Aldose reductase promotes diet-induced obesity via induction of senescence in subcutaneous adipose tissue. Obesity (Silver Spring). 2022 Aug;30(8):1647-1658. doi: 10.1002/oby.23496.

    PubMed 35894077

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Fat biopsy, Propranolol and fat biopsy and heavy water and fat biopsy in people with Obese and Normal Body Weight, run by Philip Kern at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

WAT changes during repeated exposure to cold temperatures (time frame: 28 Weeks (Summer and Winter Seasons)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02596776, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Feb 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in